CellaVision appoints Steve Ferguson as CEO
He replaces Simon Østergaard and brings over 25 years of biotech experience.
See the latest news and media coverage for CellaVision. We track all announcements, press releases, and industry mentions in real time, all in one place.
Digital hematology microscopy solutions provider
cellavision.comLast updated
In short: CellaVision appointed Steve Ferguson as CEO, launched its CE-marked Bone Marrow Aspirate Application, and reported a softer Q1 2026 financial result.
He replaces Simon Østergaard and brings over 25 years of biotech experience.
It enables collaboration on analysis to share expertise and reduce variability. Available in CE-marked markets under EU IVDR; not FDA-approved.
Resolutions approve financial statements, dividend of SEK 2.75 per share, board elections with Zlatko Rihter as new Chairman, and share repurchase authorization.
Report shows softer quarter from lower EMEA sales. They launched CE-marked Bone Marrow Aspirate Application and software upgrade.
writes about Cellavision under the headline 'Stock of the Week'
Steve Ferguson becomes new CEO at Cellavision and thus replaces Simon Østergaard with immediate effect, according to a press release. Chairman Zlatko...
Find the latest CellaVision AB (C26.MU) stock quote, history, news and other vital information to help you with your stock trading and investing.
The following resolutions were passed at the Annual General Meeting (the "AGM") of CellaVision AB (publ) on 28 April 2026 in Lund.Adoption of profit and...
Track CellaVision and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to CellaVision and other trending companies.